compani
deal add rnai platform
deal support growth risk-avers structur
increas cv/neuro/pain pipelin new rnai platform
announc global licens research collabor dicerna
pharma buy edward nash util proprietari galxc rna
interfer rnai platform progress new drug target clinic
cardio-metabol diseas neurodegener pain think
collabor make strateg financi sens strateg deal
add new riski technolog platform leverag across three
growth area includ exclus agreement neurodegener pain
neurodegener pain two therapeut area invest
consider resourc pain franchis high expect
growth asset like emgal galcanezumab /lasmiditan migrain
tanezumab pain neurodegener amyvid flortaucipir
fda approv diagnost estim beta-amyloid neurit plaqu densiti
along announc posit pet data predict brain
tau patholog alzheim diseas diagnosi top-lin sept
data readout monoclon
antibodi bace inhibitor earli symptomat ad
antibodi earli symptomat ad primari complet januari ly
also expect solanezumab data click
note titl solanezumab miss statist signific lower pt
older individu risk memori loss primari
complet juli expect collabor target give
multipl shots-on-go early-stag pipelin mitig
risk financi commit up-front cash
equiti premium deal structur heavili weight toward success-
base mileston given early-stag natur deal ad
risk-adjust revenu model new target instead view
deal interest collabor watch lli long-term
growth reiter ep risk includ price
 deal structur consist risk-avers style
note think lli agreement good job
share risk particularli early-stag asset pay
up-front cash make equiti invest
compani
repres premium close price also
elig per target commerci mileston well tier royalti
rang mid-singl low-doubl digit product sale plan collabor
target mean success-bas mileston royalti could reach
total potenti deal valu highli unlik final deal pay-out end
favor mileston royalti overal think agreement consist structur similar
early-stag deal reflect good split financi clinic risk two parti dont
see anti-trust issu aris deal hart-scott rodino clearanc period
expect deal close late nov earli dec model assum compani
make up-front invest lower ep depend
account methodolog time non-gaap basi note press releas
chang lilli non-gaap earn per share guidanc result transact
 catalyst-rich new product cycl unfold
expect top-lin data trulic rewind outcom trial /boehring ingelheim
privat jardianc heart failur pivot trial emperor-reduc -preserv like stop earli
interim analys opinion plan initi program late
aim file taltz treat ankylos spondyl regul olumi
initi psa/sl adapt initi alopecia areata track lasmiditan
lt safeti read-out gladiat posit file nda dec investor event
focus financi ranges/pipelin progress product gain hold lli
full result tanezumab osteoarthr oa trial acr share addit
safeti detail case osteonecrosi rapidli progress osteoarthr ropa seen
tanezumab treat patient vs placebo arm pfe/lli expect three remain trial
low back pain tango read earli
page
compani
valuat risk
pt assum trade ep reflect premium current
forward group averag forward price-to-earnings multipl think premium group averag
multipl justifi given lli diversifi volume-driven sale growth mid-singl digit sale
compound-annual-growth-rate oper leverag oper margin goe price
target support discount cash flow dcf intrins valu per share
risk thesi revolv around price commerci execut regulatori clinic risk
face upcom patent expir ciali alimta well recent
expir patent strattera competit pressur trulic semaglutid humalog
biosimilar insulin lispro expect off-set four launch verzenio emgal
olumi lasmiditan
compani mention note
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
suntrust robinson humphrey inc affili manag co-manag secur offer
follow compani within last month drna-u
suntrust robinson humphrey inc make market follow compani drna-u
follow compani client suntrust robinson humphrey inc invest bank servic
within last month drna-u
suntrust robinson humphrey inc affili receiv compens invest bank
servic within last month drna-u
analyst compens base upon stock price perform qualiti analysi commun skill
overal revenu profit firm includ invest bank revenu
matter polici practic firm prohibit offer favor research specif
research rate specif target price consider induc receipt busi
compens addit associ person prepar research report prohibit own
secur subject compani
page
compani
strh rate system equiti secur
dissemin research
suntrust robinson humphrey strh seek make reason effort provid research report
simultan elig client report avail publish restrict access area
websit elig client request password institut investor corpor
member press may also receiv research via third parti vendor includ thomson reuter
bloomberg factset capit iq addit distribut may done sale personnel via
email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/
pleas email research depart
contact strh sale repres
rate system effect oct
strh rate equiti secur
page
compani
rate rel broader market gener next month unless
buy stock total return expect outperform relev benchmark
hold stock total return expect perform line relev benchmark
next month unless otherwis indic
sell stock total return expect under-perform relev benchmark
next month unless otherwis indic
rate nr strh invest rate opinion stock
coverag suspend cs indic strh rate and/or target price temporarili
suspend due applic regul and/or strh manag discret previous publish
rate target price reli upon
strh analyst price target stock cover unless otherwis indic price
target repres analyst expect stock trade next month unless
otherwis indic analyst believ insuffici valuat driver and/or invest
catalyst deriv posit neg invest view may elect approv strh
research manag assign target price likewis certain stock trade may
exhibit volatil wherebi assign price target would unhelp make invest decis
research manag approv analyst may refrain assign target sub-
legend rate price target histori chart
prior rate system oct
design base total return within period
buy total return low-beta secur
reduc total return neg low beta secur
neutral total return within bound
nr rate strh provid equiti research coverag
total return price appreci dividend price target within period unless
otherwis note beta defin secur averag beta less use bloomberg
suntrust robinson humphrey rate distribut
